Novi lek u veterinarskoj kliničkoj praksi - oklacitinib maleat
New drug in veterinary clinical practice - Oclacitinib maleate
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Uvođenjem novog leka oklacitinib maleata u veterinarsku kliničku praksu napravljen
je značajan pomak u lečenju alergijskog i kliničkih slučajeva atopijskog dermatitisa
(posebno pratećeg svraba) kod pasa.
U lečenju ovih bolesti do sada su se najčešće koristili glukokortikoidi, ciklosporin i
antihistaminici. Pokazalo se da ciklosporin ima sličnu aktivnost kao i glukokortikoidi,
dok je aktivnost antihistaminika slabija. Novi lek oklacitinib maleat ima antiinflamatorni
i antipruritični efekt sličan onom koji izazivaju glukokortikoidi i ciklosporin, ali
mu (za razliku od njih) efekt brže nastupa, što mu daje veliku prednost.
Oklacitinib je imunomodulator i ima specifičan mehanizam delovanja. Deluje tako
što inhibira aktivnost enzima janus kinaza (pre svega JAK1 i JAK3), od kojih zavisi
funkcija proinflamatornih i pruritogenih citokina.
Oklacitinib je prilično bezbedan lek, ukoliko se koristi u kraćem vremenskom periodu
i u preporučenim dozama.
The introduction of a new drug oclacitinib maleate in veterinary clinical practice,
has been made a big step forward in the treatment of allergic and clinical cases of atopic
dermatitis (especially a accompanying pruritus) in dogs.
So far glucocorticoids, cyclosporine, and antihistamines were most commonly
used in the treatment of the above mentioned diseases. It has been shown that cyclosporine
has a similar activity, as glucocorticosteroids, while the activity of antihistamines
is weaker. New drug oclacitinib maleate has anti-inflammatory and antipruritic
effect similar to that caused by glucocorticoids and cyclosporine, but (unlike them) it
achieves more rapidly effect, which gives him a huge advantage.
Oclacitinib is an immunomodulator and has a specific mechanism of action. It inhibits
the activity of the Janus kinase enzymes (primarily JAK1 and JAK3), from which
the function of pro-inflammatory and pruritic cytokines depends.
Oclacitinib is a quite safe drug, if used ...in a shorter period of time, at the recommended
doses.
Кључне речи:
oklacitinib maleat / alergijski i atopijski dermatitis / psi / oclacitinib maleate / allergic and atopic dermatitis / dogsИзвор:
Veterinarski žurnal Republike Srpske, 2017, 17, 1, 119-128Издавач:
- Banja Luka : PI Veterinary Institute Republic of Srpska „Dr. Vaso Butozan“
Колекције
Институција/група
Fakultet veterinarske medicineTY - JOUR AU - Ćupić, Vitomir AU - Ivanović, Saša AU - Žugić, Gordana AU - Ćupić Miladinović, Dejana AU - Blagojević, Miloš PY - 2017 UR - https://vet-erinar.vet.bg.ac.rs/handle/123456789/2157 AB - Uvođenjem novog leka oklacitinib maleata u veterinarsku kliničku praksu napravljen je značajan pomak u lečenju alergijskog i kliničkih slučajeva atopijskog dermatitisa (posebno pratećeg svraba) kod pasa. U lečenju ovih bolesti do sada su se najčešće koristili glukokortikoidi, ciklosporin i antihistaminici. Pokazalo se da ciklosporin ima sličnu aktivnost kao i glukokortikoidi, dok je aktivnost antihistaminika slabija. Novi lek oklacitinib maleat ima antiinflamatorni i antipruritični efekt sličan onom koji izazivaju glukokortikoidi i ciklosporin, ali mu (za razliku od njih) efekt brže nastupa, što mu daje veliku prednost. Oklacitinib je imunomodulator i ima specifičan mehanizam delovanja. Deluje tako što inhibira aktivnost enzima janus kinaza (pre svega JAK1 i JAK3), od kojih zavisi funkcija proinflamatornih i pruritogenih citokina. Oklacitinib je prilično bezbedan lek, ukoliko se koristi u kraćem vremenskom periodu i u preporučenim dozama. AB - The introduction of a new drug oclacitinib maleate in veterinary clinical practice, has been made a big step forward in the treatment of allergic and clinical cases of atopic dermatitis (especially a accompanying pruritus) in dogs. So far glucocorticoids, cyclosporine, and antihistamines were most commonly used in the treatment of the above mentioned diseases. It has been shown that cyclosporine has a similar activity, as glucocorticosteroids, while the activity of antihistamines is weaker. New drug oclacitinib maleate has anti-inflammatory and antipruritic effect similar to that caused by glucocorticoids and cyclosporine, but (unlike them) it achieves more rapidly effect, which gives him a huge advantage. Oclacitinib is an immunomodulator and has a specific mechanism of action. It inhibits the activity of the Janus kinase enzymes (primarily JAK1 and JAK3), from which the function of pro-inflammatory and pruritic cytokines depends. Oclacitinib is a quite safe drug, if used in a shorter period of time, at the recommended doses. PB - Banja Luka : PI Veterinary Institute Republic of Srpska „Dr. Vaso Butozan“ T2 - Veterinarski žurnal Republike Srpske T1 - Novi lek u veterinarskoj kliničkoj praksi - oklacitinib maleat T1 - New drug in veterinary clinical practice - Oclacitinib maleate VL - 17 IS - 1 SP - 119 EP - 128 DO - 10.7251/VETJ1701119I ER -
@article{ author = "Ćupić, Vitomir and Ivanović, Saša and Žugić, Gordana and Ćupić Miladinović, Dejana and Blagojević, Miloš", year = "2017", abstract = "Uvođenjem novog leka oklacitinib maleata u veterinarsku kliničku praksu napravljen je značajan pomak u lečenju alergijskog i kliničkih slučajeva atopijskog dermatitisa (posebno pratećeg svraba) kod pasa. U lečenju ovih bolesti do sada su se najčešće koristili glukokortikoidi, ciklosporin i antihistaminici. Pokazalo se da ciklosporin ima sličnu aktivnost kao i glukokortikoidi, dok je aktivnost antihistaminika slabija. Novi lek oklacitinib maleat ima antiinflamatorni i antipruritični efekt sličan onom koji izazivaju glukokortikoidi i ciklosporin, ali mu (za razliku od njih) efekt brže nastupa, što mu daje veliku prednost. Oklacitinib je imunomodulator i ima specifičan mehanizam delovanja. Deluje tako što inhibira aktivnost enzima janus kinaza (pre svega JAK1 i JAK3), od kojih zavisi funkcija proinflamatornih i pruritogenih citokina. Oklacitinib je prilično bezbedan lek, ukoliko se koristi u kraćem vremenskom periodu i u preporučenim dozama., The introduction of a new drug oclacitinib maleate in veterinary clinical practice, has been made a big step forward in the treatment of allergic and clinical cases of atopic dermatitis (especially a accompanying pruritus) in dogs. So far glucocorticoids, cyclosporine, and antihistamines were most commonly used in the treatment of the above mentioned diseases. It has been shown that cyclosporine has a similar activity, as glucocorticosteroids, while the activity of antihistamines is weaker. New drug oclacitinib maleate has anti-inflammatory and antipruritic effect similar to that caused by glucocorticoids and cyclosporine, but (unlike them) it achieves more rapidly effect, which gives him a huge advantage. Oclacitinib is an immunomodulator and has a specific mechanism of action. It inhibits the activity of the Janus kinase enzymes (primarily JAK1 and JAK3), from which the function of pro-inflammatory and pruritic cytokines depends. Oclacitinib is a quite safe drug, if used in a shorter period of time, at the recommended doses.", publisher = "Banja Luka : PI Veterinary Institute Republic of Srpska „Dr. Vaso Butozan“", journal = "Veterinarski žurnal Republike Srpske", title = "Novi lek u veterinarskoj kliničkoj praksi - oklacitinib maleat, New drug in veterinary clinical practice - Oclacitinib maleate", volume = "17", number = "1", pages = "119-128", doi = "10.7251/VETJ1701119I" }
Ćupić, V., Ivanović, S., Žugić, G., Ćupić Miladinović, D.,& Blagojević, M.. (2017). Novi lek u veterinarskoj kliničkoj praksi - oklacitinib maleat. in Veterinarski žurnal Republike Srpske Banja Luka : PI Veterinary Institute Republic of Srpska „Dr. Vaso Butozan“., 17(1), 119-128. https://doi.org/10.7251/VETJ1701119I
Ćupić V, Ivanović S, Žugić G, Ćupić Miladinović D, Blagojević M. Novi lek u veterinarskoj kliničkoj praksi - oklacitinib maleat. in Veterinarski žurnal Republike Srpske. 2017;17(1):119-128. doi:10.7251/VETJ1701119I .
Ćupić, Vitomir, Ivanović, Saša, Žugić, Gordana, Ćupić Miladinović, Dejana, Blagojević, Miloš, "Novi lek u veterinarskoj kliničkoj praksi - oklacitinib maleat" in Veterinarski žurnal Republike Srpske, 17, no. 1 (2017):119-128, https://doi.org/10.7251/VETJ1701119I . .